| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CORT |
| Uniprot No | O00230 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-105aa |
| 氨基酸序列 | MPLSPGLLLLLLSGATATAALPLEGGPTGRDSEHMQEAAGIRKSSLLTFLAWWFEWTSQASAGPLIGEEAREVARRQEGAPPQQSARRDRMPCRNFFWKTFSSCK |
| 预测分子量 | 11,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CORT(皮质酮)重组蛋白研究的模拟参考文献示例(注：文献名为假设性示例，建议通过学术数据库检索真实文献)：
---
1. **文献名称**: *Expression and Purification of Recombinant Corticosterone-Binding Globulin (CBG) in Mammalian Cells*
**作者**: Smith A, et al.
**摘要**: 研究报道了在HEK293细胞中重组表达人源皮质酮结合球蛋白(CBG)，通过亲和层析纯化获得高活性蛋白，并验证其在体外调节皮质酮生物利用度的功能，为激素递送机制研究提供工具。
2. **文献名称**: *Development of a Bacterial System for Recombinant CORT-Binding Receptor Production*
**作者**: Lee C, et al.
**摘要**: 利用大肠杆菌表达系统成功制备重组糖皮质激素受体(GR)的配体结合域，通过体外结合实验证实其对皮质酮(CORT)的高亲和力，为受体-激素互作的结构研究奠定基础。
3. **文献名称**: *Engineering a Fluorescent CORT Sensor Protein via Recombinant Fusion Technology*
**作者**: Zhang Y, et al.
**摘要**: 通过将CORT结合蛋白与绿色荧光蛋白(GFP)融合表达，开发了一种基于荧光共振能量转移(FRET)的重组传感器，可实时监测活细胞中皮质酮浓度的动态变化。
---
**建议**：实际研究中推荐使用PubMed、Google Scholar等平台，以“recombinant corticosterone-binding protein”或“recombinant glucocorticoid receptor”为关键词检索最新文献。
CORT (corticosterone) is a steroid hormone primarily produced in the adrenal cortex of rodents, acting as their main glucocorticoid, while in humans, cortisol serves this role. It plays a critical role in regulating stress responses, metabolism, immune function, and neuronal activity through the hypothalamic-pituitary-adrenal (HPA) axis. Recombinant CORT refers to the engineered production of this hormone using biotechnology, typically by inserting the gene encoding enzymes involved in corticosterone synthesis (e.g., cytochrome P450 family proteins) into host systems like bacteria, yeast, or mammalian cells. These systems are optimized to express and secrete the protein, which is then purified for research or therapeutic use.
The development of recombinant CORT addresses challenges in natural extraction, such as low yield, ethical concerns, and batch variability. It enables precise control over hormone concentrations in experimental settings, facilitating studies on stress physiology, neuroendocrine disorders, and glucocorticoid receptor signaling. In pharmaceuticals, recombinant CORT aids in drug testing for conditions like adrenal insufficiency, chronic inflammation, or depression. Its consistency and scalability also support the creation of standardized diagnostic tools and therapies. However, species-specific differences—rodent CORT vs. human cortisol—require careful interpretation in translational research. Advances in recombinant technology continue to refine its bioactivity and delivery methods, enhancing its utility in both basic science and clinical applications.
×
